The release does not break down the $1.46 billion by stage, and it does not say how many targets or programs that figure covers. Bloomberg valued the deal at up to $1.86 billion, while the disclosed upfront and milestone figures total about $1.5 billion. The companies have not explained the gap. AstraZeneca's executive vice president for biopharmaceuticals R&D tied the agreement to target selection, calling it one of the most critical decisions in R&D.
For attorneys, the headline number is mostly contingent. Nearly all of the value depends on future development and sales milestones, so the $40 million upfront is the only near-term certainty. Watch for the program count and milestone schedule in future filings, and for any disclosure of IP ownership and option terms for selected programs, which will determine how the exclusivity rights play out. The deal also tests whether machine-learning-led target discovery can produce programs AstraZeneca actually advances, a question that matters for AstraZeneca's push toward 20 new medicines by 2030 and its earlier MASH trial failure last year.